{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:28:52Z","timestamp":1790724532405,"version":"4.1.0"},"reference-count":255,"publisher":"Elsevier","isbn-type":[{"value":"9780443432361","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.acr.2026.02.006","type":"book-chapter","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:47:53Z","timestamp":1773146873000},"page":"267-319","source":"Crossref","is-referenced-by-count":1,"title":["Advancing clinical translation of oncolytic adenoviruses"],"prefix":"10.1016","author":[{"given":"Margarita","family":"Romanenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Davydova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.acr.2026.02.006_bib255","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1021\/mp200161f","article-title":"A comparative study of neural and mesenchimal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma","volume":"8","author":"Ahmed","year":"2011","journal-title":"Molecular Pharmaceutics"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0001","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11095-020-02818-8","article-title":"Tuning the physicochemical characteristics of particle-based carriers for intraperitoneal local chemotherapy","volume":"37","author":"Alavi","year":"2020","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0002","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","article-title":"Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer","volume":"114","author":"Alba","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2015.194","article-title":"Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs","volume":"24","author":"Alonso-Padilla","year":"2016","journal-title":"Mol Ther"},{"issue":"13","key":"10.1016\/bs.acr.2026.02.006_bib0004","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1073\/pnas.81.13.4023","article-title":"Altered mRNA splicing in monkey cells abortively infected with human adenovirus may be responsible for inefficient synthesis of the virion fiber polypeptide","volume":"81","author":"Anderson","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: Implications for targeting of viral vectors","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"571","key":"10.1016\/bs.acr.2026.02.006_bib0006","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc6659","article-title":"Systemic cancer therapy with engineered adenovirus that evades innate immunity","volume":"12","author":"Atasheva","year":"2020","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/v14081835","article-title":"Properties of adenovirus vectors with increased affinity to DSG2 and the potential benefits of oncolytic approaches and gene therapy","volume":"14","author":"Bahlmann","year":"2022","journal-title":"Viruses"},{"issue":"49","key":"10.1016\/bs.acr.2026.02.006_bib0008","doi-asserted-by":"crossref","first-page":"eabl8213","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0009","doi-asserted-by":"crossref","first-page":"eaax3567","DOI":"10.1126\/sciadv.aax3567","article-title":"Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor","volume":"5","author":"Baker","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/bs.acr.2026.02.006_bib0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","article-title":"Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer","volume":"20","author":"Barton","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0011","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/mt.2008.172","article-title":"Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate","volume":"16","author":"Barton","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/bs.acr.2026.02.006_bib0012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.omto.2022.12.007","article-title":"Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors","volume":"28","author":"Basnet","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"19","key":"10.1016\/bs.acr.2026.02.006_bib0013","doi-asserted-by":"crossref","first-page":"10087","DOI":"10.1128\/JVI.02425-09","article-title":"Development of a targeted gene vector platform based on simian adenovirus serotype 24","volume":"84","author":"Belousova","year":"2010","journal-title":"J Virol"},{"issue":"33","key":"10.1016\/bs.acr.2026.02.006_bib0014","doi-asserted-by":"crossref","first-page":"53414","DOI":"10.18632\/oncotarget.10800","article-title":"Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43","volume":"7","author":"Belousova","year":"2016","journal-title":"Oncotarget"},{"issue":"5304","key":"10.1016\/bs.acr.2026.02.006_bib0015","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0016","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1073\/pnas.74.8.3171","article-title":"Spliced segments at the 5\u2032 terminus of adenovirus 2 late mRNA","volume":"74","author":"Berget","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0017","first-page":"1253","article-title":"Animal models in human adenovirus research","volume":"10","author":"Bertzbach","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/bs.acr.2026.02.006_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/193045a0","article-title":"Inoculation of pigs with adenoviruses of man","volume":"193","author":"Betts","year":"1962","journal-title":"Nature"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0019","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-11-3213","article-title":"Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs","volume":"18","author":"Beyer","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5286","key":"10.1016\/bs.acr.2026.02.006_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0021","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","article-title":"Restricted replication of human adenovirus type 5 in mouse cell lines","volume":"14","author":"Blair","year":"1989","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0022","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41467-025-56482-w","article-title":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: The phase 1a PROTA trial","volume":"16","author":"Block","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0023","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/cgt.2009.12","article-title":"Deletion of the E3-6.7K\/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters","volume":"16","author":"Bortolanza","year":"2009","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0024","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/1878-0261.13561","article-title":"Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma","volume":"18","author":"Bots","year":"2024","journal-title":"Mol Oncol"},{"issue":"5-6","key":"10.1016\/bs.acr.2026.02.006_bib0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/hum.2021.216","article-title":"Nonhuman primate adenoviruses of the human adenovirus B species are potent and broadly acting oncolytic vector candidates","volume":"33","author":"Bots","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0026","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0027","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions","volume":"86","author":"Bradley","year":"2012","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001142","article-title":"Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X","volume":"6","author":"Bradshaw","year":"2010","journal-title":"PLoS Pathog"},{"issue":"17","key":"10.1016\/bs.acr.2026.02.006_bib0029","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.1128\/JVI.00462-13","article-title":"Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors","volume":"87","author":"Bruder","year":"2013","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/v12121399","article-title":"Species D adenoviruses as oncolytic viral vectors","volume":"12","author":"Bullard","year":"2020","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0031","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0032","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1089\/hum.2013.215","article-title":"CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy","volume":"25","author":"Camacho","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0033","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/14712598.2019.1595582","article-title":"Oncolytic adenoviruses: A game changer approach in the battle between cancer and the immune system","volume":"19","author":"Cervera-Carrascon","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0034","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/v11050395","article-title":"Sialic acid-containing glycans as cellular receptors for ocular human adenoviruses: Implications for tropism and treatment","volume":"11","author":"Chandra","year":"2019","journal-title":"Viruses"},{"issue":"21","key":"10.1016\/bs.acr.2026.02.006_bib0035","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-11-0968","article-title":"Species D adenoviruses as oncolytics against B-cell cancers","volume":"17","author":"Chen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0036","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/cgt.2011.47","article-title":"Mining the adenovirus virome for oncolytics against multiple solid tumor types","volume":"18","author":"Chen","year":"2011","journal-title":"Cancer Gene Ther"},{"issue":"16","key":"10.1016\/bs.acr.2026.02.006_bib0037","doi-asserted-by":"crossref","first-page":"26871","DOI":"10.18632\/oncotarget.15845","article-title":"A novel oncolytic adenovirus based on simian adenovirus serotype 24","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0038","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0264-410X(96)00174-0","article-title":"Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees","volume":"15","author":"Chengalvala","year":"1997","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0039","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.virusres.2003.11.018","article-title":"Recombinant avian adenovirus CELO expressing the human interleukin-2: Characterization in vitro, in ovo and in vivo","volume":"100","author":"Cherenova","year":"2004","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54939-9","article-title":"Unravelling receptor and RGD Motif dependence of retargeted adenoviral vectors using advanced tumor model systems","volume":"9","author":"Chernyavska","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0092-8674(77)90180-5","article-title":"An amazing sequence arrangement at the 5\u2032 ends of adenovirus 2 messenger RNA","volume":"12","author":"Chow","year":"1977","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0042","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2011.08.003","article-title":"Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea","volume":"312","author":"Coburn","year":"2011","journal-title":"Cancer Lett"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0043","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2012.162","article-title":"Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery","volume":"20","author":"Coughlan","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/bs.acr.2026.02.006_bib0044","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1525-0016(16)34467-7","article-title":"Replication of human adenoviruses in non-human cells in vitro and in vivo","volume":"21","author":"Crosby","year":"2013","journal-title":"Molecular Therapy"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0045","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1349-7006.2009.01407.x","article-title":"In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy","volume":"101","author":"Davydova","year":"2010","journal-title":"Cancer Sci"},{"issue":"20","key":"10.1016\/bs.acr.2026.02.006_bib0046","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005514","article-title":"Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy","volume":"11","author":"Deycmar","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0048","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/gt.2014.2","article-title":"Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood","volume":"21","author":"Di","year":"2014","journal-title":"Gene Ther"},{"issue":"14","key":"10.1016\/bs.acr.2026.02.006_bib0049","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1128\/JVI.76.14.6893-6899.2002","article-title":"Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX","volume":"76","author":"Dmitriev","year":"2002","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/cgt.2010.52","article-title":"Dual E1A oncolytic adenovirus: Targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3\/MUC1 and hTERT","volume":"18","author":"Doloff","year":"2011","journal-title":"Cancer Gene Ther"},{"issue":"6108","key":"10.1016\/bs.acr.2026.02.006_bib0051","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.1226625","article-title":"Coagulation factor X activates innate immunity to human species C adenovirus","volume":"338","author":"Doronin","year":"2012","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0052","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/viro.2002.1772","article-title":"Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus","volume":"305","author":"Doronin","year":"2003","journal-title":"Virology"},{"key":"10.1016\/bs.acr.2026.02.006_bib0053","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","article-title":"Oncolytic group B adenovirus enadenotucirev mediates non-apoptotic cell death with membrane disruption and release of inflammatory mediators","volume":"4","author":"Dyer","year":"2017","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0054","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41577-018-0005-7","article-title":"Nonhuman primate models of human viral infections","volume":"18","author":"Estes","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006561","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced\/metastatic epithelial cancer: A phase I clinical trial (SPICE)","volume":"11","author":"Fakih","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0056","doi-asserted-by":"crossref","first-page":"506","DOI":"10.24272\/j.issn.2095-8137.2019.063","article-title":"Chromosomal level assembly and population sequencing of the Chinese tree shrew genome","volume":"40","author":"Fan","year":"2019","journal-title":"Zool Res"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0057","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1053\/j.gastro.2012.07.110","article-title":"A porcine model of familial adenomatous polyposis","volume":"143","author":"Flisikowska","year":"2012","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/bs.acr.2026.02.006_bib0058","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0059","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0060","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/bs.acr.2026.02.006_bib0061","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"Gallego Perez-Larraya","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0062","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients","volume":"30","author":"Garcia","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0063","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Garcia-Carbonero","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0064","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib253","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/cgt.2010.4","article-title":"Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study","volume":"17","author":"Garcia-Castro","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/bs.acr.2026.02.006_bib256","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2018.12.022","article-title":"Extracellular vesicles anhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice","volume":"294","author":"Garofalo","year":"2019","journal-title":"J Contr Rel"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0065","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/hum.2008.053","article-title":"Coagulation factors determine tumor transduction in vivo","volume":"19","author":"Gimenez-Alejandre","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/bs.acr.2026.02.006_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.698999","article-title":"Susceptibility of dog, hamster, and mouse cells to the replication-competent adenovirus 11p E1\/E3 green fluorescence protein vector has implications for the selection of animal vaccine models","volume":"12","author":"Gokumakulapalle","year":"2021","journal-title":"Front Microbiol"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0067","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/mt.2009.152","article-title":"Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5\/Ad35 vectors","volume":"17","author":"Greig","year":"2009","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0068","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2967\/jnumed.112.115493","article-title":"Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene","volume":"54","author":"Grunwald","year":"2013","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0069","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3181\/00379727-96-23466","article-title":"Susceptibility of pig kidney tissue cultures to certain viruses","volume":"96","author":"Guerin","year":"1957","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0070","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/mp8000974","article-title":"Scavenger receptor A: A new route for adenovirus 5","volume":"6","author":"Haisma","year":"2009","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0071","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0072","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1349-7006.2007.00408.x","article-title":"Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster","volume":"98","author":"Hara","year":"2007","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0073","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008999","article-title":"Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: An investigator-initiated trial","volume":"12","author":"He","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/bs.acr.2026.02.006_bib0074","series-title":"Fields virology: DNA viruses","first-page":"98","article-title":"Adenoviridae: The viruses and their replication","author":"Hearing","year":"2021"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0075","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1128\/JVI.77.11.6562-6566.2003","article-title":"Extensive cross-reactivity of CD4+ adenovirus-specific T cells: Implications for immunotherapy and gene therapy","volume":"77","author":"Heemskerk","year":"2003","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0076","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0077","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.ymthe.2023.04.006","article-title":"Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial","volume":"31","author":"Heo","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/bs.acr.2026.02.006_bib0078","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1472-6750-6-36","article-title":"Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli","volume":"6","author":"Hoffmann","year":"2006","journal-title":"BMC Biotechnol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0079","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.jid.5701131","article-title":"Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma","volume":"128","author":"Hoffmann","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/viro.1999.9712","article-title":"Use of site-specific mutagenesis and monoclonal antibodies to map regions of CD46 that interact with measles virus H protein","volume":"258","author":"Hsu","year":"1999","journal-title":"Virology"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0081","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1128\/jvi.70.7.4502-4508.1996","article-title":"Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells","volume":"70","author":"Huang","year":"1996","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0082","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/1878-0261.12628","article-title":"A SIRPalpha-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer","volume":"14","author":"Huang","year":"2020","journal-title":"Mol Oncol"},{"issue":"10-11","key":"10.1016\/bs.acr.2026.02.006_bib0083","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41417-019-0156-0","article-title":"Identification of folate receptor alpha (FRalpha) binding oligopeptides and their evaluation for targeted virotherapy applications","volume":"27","author":"Hulin-Curtis","year":"2020","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0084","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.vaccine.2009.10.091","article-title":"Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive","volume":"28","author":"Hutnick","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/bs.acr.2026.02.006_bib0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s42003-018-0163-y","article-title":"Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1","volume":"1","author":"Isakson","year":"2018","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0086","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13046-024-03219-0","article-title":"Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors","volume":"43","author":"Jirovec","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0087","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/JVI.80.7.3549-3558.2006","article-title":"Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species","volume":"80","author":"Jogler","year":"2006","journal-title":"Journal of Virology"},{"issue":"35","key":"10.1016\/bs.acr.2026.02.006_bib0088","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1016\/j.vaccine.2010.06.050","article-title":"Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28","volume":"28","author":"Kahl","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/bs.acr.2026.02.006_bib0089","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2021.02.018","article-title":"Overcoming the barriers to optimization of adenovirus delivery using biomaterials: Current status and future perspective","volume":"332","author":"Kasala","year":"2021","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jmb.2009.03.016","article-title":"Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody","volume":"388","author":"Kashentseva","year":"2009","journal-title":"J Mol Biol"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0091","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.01392-12","article-title":"Circulating antibodies and macrophages as modulators of adenovirus pharmacology","volume":"87","author":"Khare","year":"2013","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0092","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/mt.2011.71","article-title":"Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer","volume":"19","author":"Khare","year":"2011","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0093","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.05760-11","article-title":"Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors","volume":"86","author":"Khare","year":"2012","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0094","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","article-title":"A phase I clinical trial of Ad5\/3-Delta24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","volume":"130","author":"Kim","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0095","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/JVI.74.6.2804-2813.2000","article-title":"Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein","volume":"74","author":"Kirby","year":"2000","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0096","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/cancers11020198","article-title":"Rodents versus pig model for assessing the performance of serotype chimeric Ad5\/3 oncolytic adenoviruses","volume":"11","author":"Koodie","year":"2019","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0097","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0098","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/cgt.2014.67","article-title":"An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment","volume":"22","author":"Kostova","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0099","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"Kuhn","year":"2008","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1172\/JCI9180","article-title":"Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen","volume":"106","author":"Kurihara","year":"2000","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/bs.acr.2026.02.006_bib0101","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0102","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","article-title":"Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer","volume":"157","author":"LaRocca","year":"2015","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0103","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1162\/1535350041464874","article-title":"Fluorescently labeled adenovirus with pIX-EGFP for vector detection","volume":"3","author":"Le","year":"2004","journal-title":"Mol Imaging"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0104","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.7150\/thno.105163","article-title":"Transferrin-binding domain inserted-adenovirus hexon engineering enables systemic immune evasion and intratumoral T-cell activation","volume":"15","author":"Lee","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40425-018-0350-x","article-title":"Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells","volume":"6","author":"Lei","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"Pt 10","key":"10.1016\/bs.acr.2026.02.006_bib0106","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1099\/vir.0.82079-0","article-title":"Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: Manufacture on PER.C6 cells, tropism and immunogenicity","volume":"87","author":"Lemckert","year":"2006","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004657","article-title":"Human adenovirus 52 uses sialic acid-containing glycoproteins and the coxsackie and adenovirus receptor for binding to target cells","volume":"11","author":"Lenman","year":"2015","journal-title":"PLoS Pathog"},{"issue":"18","key":"10.1016\/bs.acr.2026.02.006_bib0108","doi-asserted-by":"crossref","first-page":"E4264","DOI":"10.1073\/pnas.1716900115","article-title":"Polysialic acid is a cellular receptor for human adenovirus 52","volume":"115","author":"Lenman","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0109","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1128\/JVI.75.11.5405-5409.2001","article-title":"Integrin alpha(v)beta1 is an adenovirus coreceptor","volume":"75","author":"Li","year":"2001","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0110","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/gt.2008.179","article-title":"A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients","volume":"16","author":"Li","year":"2009","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0111","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/22221751.2021.1895679","article-title":"Chinese tree shrew: A permissive model for in vitro and in vivo replication of human adenovirus species B","volume":"10","author":"Li","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"17","key":"10.1016\/bs.acr.2026.02.006_bib0112","first-page":"6428","article-title":"A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin","volume":"61","author":"Li","year":"2001","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"10.1016\/bs.acr.2026.02.006_bib0113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/08830180490265556","article-title":"Functions and mechanisms of action of the adenovirus E3 proteins","volume":"23","author":"Lichtenstein","year":"2004","journal-title":"Int Rev Immunol"},{"issue":"5995","key":"10.1016\/bs.acr.2026.02.006_bib0114","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1126\/science.1187433","article-title":"Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks","volume":"329","author":"Liu","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0115","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jmb.2010.11.043","article-title":"Model of the trimeric fiber and its interactions with the pentameric penton base of human adenovirus by cryo-electron microscopy","volume":"406","author":"Liu","year":"2011","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0116","article-title":"Human adenovirus type 17 from species D transduces endothelial cells and human CD46 is involved in cell entry","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"issue":"10255","key":"10.1016\/bs.acr.2026.02.006_bib0117","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0118","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.gt.3302146","article-title":"Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53","volume":"11","author":"Logunov","year":"2004","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004673","article-title":"Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo","volume":"11","author":"Ma","year":"2015","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0120","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3390\/cancers12061403","article-title":"Spectrum-wide exploration of human adenoviruses for breast cancer therapy","volume":"12","author":"Mach","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0121","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0122","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/cgt.2012.79","article-title":"HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice","volume":"19","author":"MacLeod","year":"2012","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0123","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.cgt.7701027","article-title":"Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2\/neu","volume":"14","author":"Magnusson","year":"2007","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016792","article-title":"Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging","volume":"6","author":"Mathis","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/cancers12030619","article-title":"Modeling the efficacy of oncolytic adenoviruses in vitro and in vivo: Current and future perspectives","volume":"12","author":"McKenna","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.acr.2026.02.006_bib0126","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.virol.2016.07.026","article-title":"Complete replication-competent adenovirus 11p vectors with E1 or E3 insertions show improved heat stability","volume":"497","author":"Mei","year":"2016","journal-title":"Virology"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0127","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tim.2011.11.002","article-title":"The pig: A model for human infectious diseases","volume":"20","author":"Meurens","year":"2012","journal-title":"Trends Microbiol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14712598.2016.1100162","article-title":"The use of the NIS reporter gene for optimizing oncolytic virotherapy","volume":"16","author":"Miller","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0130","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1128\/JVI.73.7.6056-6065.1999","article-title":"Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors","volume":"73","author":"Miyazawa","year":"1999","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0131","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1128\/JVI.76.4.1578-1587.2002","article-title":"Adenovirus E3-6.7K maintains calcium homeostasis and prevents apoptosis and arachidonic acid release","volume":"76","author":"Moise","year":"2002","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0132","article-title":"Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma","volume":"6","author":"Monberg","year":"2025","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0133","article-title":"Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy","volume":"32","author":"Morales-Molina","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003645","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: A phase 1 clinical trial","volume":"9","author":"Moreno","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/bs.acr.2026.02.006_bib0135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/toxsci\/65.2.256","article-title":"Porcine toxicology studies of SCH 58500, an adenoviral vector for the p53 gene","volume":"65","author":"Morrissey","year":"2002","journal-title":"Toxicological Sciences"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0136","doi-asserted-by":"crossref","first-page":"9768","DOI":"10.1038\/s41467-024-54049-9","article-title":"Structure-derived insights from blood factors binding to the surfaces of different adenoviruses","volume":"15","author":"Mudrick","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44298-023-00001-5","article-title":"Broad sialic acid usage amongst species D human adenovirus","volume":"1","author":"Mundy","year":"2023","journal-title":"Npj Viruses"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0138","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): Results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0139","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010016","article-title":"First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments","volume":"12","author":"Naing","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1006\/mthe.2001.0303","article-title":"Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters","volume":"3","author":"Nakano","year":"2001","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0141","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0142","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.mt.6300096","article-title":"Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy","volume":"15","author":"Nasu","year":"2007","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0143","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77664-4","article-title":"An in silico approach uncovering the competency of oncolytic human adenovirus 52 for targeted breast cancer virotherapy","volume":"14","author":"Naveed","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/bs.acr.2026.02.006_bib0144","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/OV.S155946","article-title":"Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer","volume":"7","author":"Nguyen","year":"2018","journal-title":"Oncolytic Virother"},{"key":"10.1016\/bs.acr.2026.02.006_bib0145","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.21","article-title":"Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers","volume":"3","author":"Nguyen","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0146","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/mthe.2001.0489","article-title":"Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus","volume":"4","author":"Nicklin","year":"2001","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0147","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.2267","article-title":"The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis","volume":"17","author":"Nilsson","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/bs.acr.2026.02.006_bib0148","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12943-015-0479-x","article-title":"Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model","volume":"14","author":"Nistal-Villan","year":"2015","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0149","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13014-020-01593-5","article-title":"A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)","volume":"15","author":"O'Cathail","year":"2020","journal-title":"Radiat Oncol"},{"issue":"22","key":"10.1016\/bs.acr.2026.02.006_bib0150","doi-asserted-by":"crossref","first-page":"10154","DOI":"10.1158\/0008-5472.CAN-05-1871","article-title":"Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region","volume":"65","author":"Ono","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/bs.acr.2026.02.006_bib0151","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0152","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006558","article-title":"Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity","volume":"13","author":"Ono","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0153","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/v15010182","article-title":"Development of oncolytic vectors based on human adenovirus type 6 for cancer treatment","volume":"15","author":"Osipov","year":"2023","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0154","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"issue":"17","key":"10.1016\/bs.acr.2026.02.006_bib0155","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","article-title":"Safety, efficacy, and biological data of T-cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial","volume":"30","author":"Pakola","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0156","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1471-0528.1981.tb00962.x","article-title":"Clotting and fibrinolytic activities in peritoneal fluid","volume":"88","author":"Pattinson","year":"1981","journal-title":"Br J Obstet Gynaecol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0157","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ab.2006.04.032","article-title":"A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers","volume":"354","author":"Peng","year":"2006","journal-title":"Anal Biochem"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0158","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020732118","article-title":"Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46","volume":"118","author":"Persson","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0159","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/neuonc\/noab128","article-title":"An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus","volume":"23","author":"Phillips","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/mt.2012.287","article-title":"SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors","volume":"21","author":"Piccolo","year":"2013","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0161","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007552","article-title":"ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: A randomized phase 2 study investigating clinical outcomes and the tumor microenvironment","volume":"11","author":"Ponce","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0162","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/jvi.67.1.101-111.1993","article-title":"Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus)","volume":"67","author":"Prince","year":"1993","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0163","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30916-6","article-title":"KRAS(G12D) and TP53(R167H) cooperate to induce pancreatic ductal adenocarcinoma in sus scrofa pigs","volume":"8","author":"Principe","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/bs.acr.2026.02.006_bib0164","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3181\/00379727-116-29197","article-title":"Enhancement of adenovirus growth in African green monkey kidney cell cultures by SV40","volume":"116","author":"Rabson","year":"1964","journal-title":"Proc. Sot. Exp. Biol. Med"},{"key":"10.1016\/bs.acr.2026.02.006_bib0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors \u2013 an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0166","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/bjc.2013.509","article-title":"Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: A multitumour array analysis","volume":"109","author":"Reeh","year":"2013","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0167","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/sj.gt.3300941","article-title":"Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector","volume":"6","author":"Reynolds","year":"1999","journal-title":"Gene Ther"},{"issue":"4S1","key":"10.1016\/bs.acr.2026.02.006_bib0168","first-page":"825","article-title":"A novel immunocompetent, adenovirus-permissive model to analyze the oncolytic potential and anti-tumor immunity of human adenovirus against metastatic breast cancer","volume":"32","author":"Robert","year":"2024","journal-title":"Molecular Therapy"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0169","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/v16040567","article-title":"Oncolytic adenovirus for the targeting of paclitaxel-resistant breast cancer stem cells","volume":"16","author":"Robert","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.acr.2026.02.006_bib0170","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.omto.2021.03.002","article-title":"Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion","volume":"20","author":"Robertson","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0171","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1128\/JVI.72.10.7909-7915.1998","article-title":"The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F","volume":"72","author":"Roelvink","year":"1998","journal-title":"J Virol"},{"issue":"4S1","key":"10.1016\/bs.acr.2026.02.006_bib0172","first-page":"413","article-title":"The safety and biodistribution profiles of systemically delivered oncolytic adenovirus in pigs","volume":"30","author":"Romanenko","year":"2022","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0173","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101641","article-title":"Adenovirus type 6: Subtle structural distinctions from adenovirus type 5 result in essential differences in properties and perspectives for gene therapy","volume":"13","author":"Romanenko","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0174","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus icovir-5 in patients with advanced tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0175","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1038\/oncsis.2016.19","article-title":"A porcine model of osteosarcoma","volume":"5","author":"Saalfrank","year":"2016","journal-title":"Oncogenesis"},{"issue":"24","key":"10.1016\/bs.acr.2026.02.006_bib0176","doi-asserted-by":"crossref","first-page":"13448","DOI":"10.1128\/JVI.77.24.13448-13454.2003","article-title":"Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5","volume":"77","author":"Salone","year":"2003","journal-title":"J Virol"},{"issue":"26","key":"10.1016\/bs.acr.2026.02.006_bib0177","doi-asserted-by":"crossref","first-page":"18041","DOI":"10.18632\/oncotarget.24710","article-title":"Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer","volume":"9","author":"Salzwedel","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0178","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/hum.2007.124","article-title":"Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells","volume":"20","author":"Sandberg","year":"2009","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.006_bib0179","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1128\/JVI.79.10.6516-6522.2005","article-title":"Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates","volume":"79","author":"Santra","year":"2005","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0180","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/gt.2008.56","article-title":"Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies","volume":"15","author":"Sarkioja","year":"2008","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0181","article-title":"Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin","volume":"33","author":"Sato-Dahlman","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0182","article-title":"Bovine adenoviral vector-based platform for vaccine development","volume":"13","author":"Sayedahmed","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"38","key":"10.1016\/bs.acr.2026.02.006_bib0183","doi-asserted-by":"crossref","first-page":"63620","DOI":"10.18632\/oncotarget.18872","article-title":"A validated, transitional and translational porcine model of hepatocellular carcinoma","volume":"8","author":"Schachtschneider","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acr.2026.02.006_bib0184","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1323422","article-title":"Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro","volume":"14","author":"Segatto","year":"2024","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/bs.acr.2026.02.006_bib0185","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.1128\/JVI.77.17.9183-9191.2003","article-title":"Adenovirus type 11 uses CD46 as a cellular receptor","volume":"77","author":"Segerman","year":"2003","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0186","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/hum.2009.082","article-title":"Infection and killing of multiple myeloma by adenoviruses","volume":"21","author":"Senac","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0187","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/JVI.00354-11","article-title":"Using the whole-genome sequence to characterize and name human adenoviruses","volume":"85","author":"Seto","year":"2011","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0188","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bjc.2015.481","article-title":"Oncolytic viruses: Finally delivering","volume":"114","author":"Seymour","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0189","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virol.2009.01.008","article-title":"Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model","volume":"386","author":"Sharma","year":"2009","journal-title":"Virology"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0190","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.cgt.7700822","article-title":"Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors","volume":"12","author":"Shashkova","year":"2005","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0191","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.virol.2009.08.038","article-title":"Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents","volume":"394","author":"Shashkova","year":"2009","journal-title":"Virology"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0192","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/sj.mt.6300064","article-title":"Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus","volume":"15","author":"Shashkova","year":"2007","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0193","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/JVI.79.2.1053-1061.2005","article-title":"Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0194","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1111\/cas.15903","article-title":"Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model","volume":"114","author":"Shinoda","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/bs.acr.2026.02.006_bib0195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1\u20132","key":"10.1016\/bs.acr.2026.02.006_bib0196","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virusres.2006.07.009","article-title":"Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors","volume":"122","author":"Short","year":"2006","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0197","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1078-0432.CCR-22-2046","article-title":"Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti-PD-1-resistant advanced melanoma","volume":"29","author":"Shoushtari","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10.1016\/bs.acr.2026.02.006_bib0198","doi-asserted-by":"crossref","first-page":"13022","DOI":"10.1073\/pnas.1000475107","article-title":"Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD\/SCID\/IL2r gamma(null) humanized mice","volume":"107","author":"Shultz","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0199","article-title":"Porcine cancer models for translational oncology","volume":"1","author":"Sieren","year":"2014","journal-title":"Mol Cell Oncol"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0200","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1128\/JVI.78.9.4454-4462.2004","article-title":"The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3","volume":"78","author":"Sirena","year":"2004","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0201","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/cgt.2009.36","article-title":"New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster","volume":"16","author":"Spencer","year":"2009","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.virol.2007.07.022","article-title":"Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus","volume":"369","author":"Steel","year":"2007","journal-title":"Virology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0203","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94573-y","article-title":"A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation","volume":"11","author":"Stepanenko","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0204","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/jvi.69.5.2850-2857.1995","article-title":"Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain","volume":"69","author":"Stevenson","year":"1995","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0205","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tim.2007.10.001","article-title":"Cell integrins: Commonly used receptors for diverse viral pathogens","volume":"15","author":"Stewart","year":"2007","journal-title":"Trends Microbiol"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0206","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1158\/0008-5472.CAN-09-0645","article-title":"Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses","volume":"69","author":"Strauss","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0207","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19810-4","article-title":"Species-specific transcriptomic changes upon respiratory syncytial virus infection in cotton rats","volume":"12","author":"Strickland","year":"2022","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0208","first-page":"3348","article-title":"The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses","volume":"8","author":"Suzuki","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0209","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0300985811402846","article-title":"Swine as models in biomedical research and toxicology testing","volume":"49","author":"Swindle","year":"2012","journal-title":"Vet Pathol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.virusres.2011.09.031","article-title":"Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer","volume":"163","author":"Tandon","year":"2012","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0211","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CJI.0b013e318238a115","article-title":"Potent antietumor immunity in mice induced by vaccination with an ovine atadenovirus vector","volume":"35","author":"Tang","year":"2012","journal-title":"J Immunother"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0212","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/CVI.00207-14","article-title":"Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors","volume":"21","author":"Teigler","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0213","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41231-023-00144-w","article-title":"Oncolytic virus-based suicide gene therapy for cancer treatment: A perspective of the clinical trials conducted at Henry Ford Health","volume":"8","author":"Thoidingjam","year":"2023","journal-title":"Transl Med Commun"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0214","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0215","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Research"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0216","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010859","article-title":"Binding of adenovirus species C hexon to prothrombin and the influence of hexon on vector properties in vitro and in vivo","volume":"18","author":"Tian","year":"2022","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0217","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/JVI.06181-11","article-title":"Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection","volume":"86","author":"Trinh","year":"2012","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0218","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/gt.2010.63","article-title":"A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer","volume":"17","author":"Trujillo","year":"2010","journal-title":"Gene Ther"},{"issue":"Pt 1","key":"10.1016\/bs.acr.2026.02.006_bib0219","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1042\/bj3300163","article-title":"Molecular cloning of a murine homologue of membrane cofactor protein (CD46): Preferential expression in testicular germ cells","volume":"330","author":"Tsujimura","year":"1998","journal-title":"Biochem J"},{"issue":"24","key":"10.1016\/bs.acr.2026.02.006_bib0220","doi-asserted-by":"crossref","first-page":"12109","DOI":"10.1128\/JVI.01370-06","article-title":"A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells","volume":"80","author":"Tuve","year":"2006","journal-title":"J Virol"},{"issue":"19","key":"10.1016\/bs.acr.2026.02.006_bib0221","doi-asserted-by":"crossref","first-page":"27926","DOI":"10.18632\/oncotarget.8545","article-title":"Pseudotyped alphavbeta6 integrin-targeted adenovirus vectors for ovarian cancer therapies","volume":"7","author":"Uusi-Kerttula","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0222","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1128\/JVI.76.6.2753-2762.2002","article-title":"Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished","volume":"76","author":"van Beusechem","year":"2002","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0223","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: A phase I clinical trial including correlative studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.006_bib0224","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/cgt.2014.22","article-title":"Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model","volume":"21","author":"Vijayalingam","year":"2014","journal-title":"Cancer Gene Ther"},{"issue":"10269","key":"10.1016\/bs.acr.2026.02.006_bib0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.006_bib0226","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"issue":"13","key":"10.1016\/bs.acr.2026.02.006_bib0227","doi-asserted-by":"crossref","first-page":"eade6790","DOI":"10.1126\/sciadv.ade6790","article-title":"Ultralow-dose binary oncolytic\/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies","volume":"9","author":"Wang","year":"2023","journal-title":"Sci Adv"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0228","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1128\/JVI.00205-12","article-title":"A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses","volume":"86","author":"Wang","year":"2012","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/bs.acr.2026.02.006_bib0229","doi-asserted-by":"crossref","first-page":"10841","DOI":"10.1128\/JVI.01425-15","article-title":"Intracellular signaling and desmoglein 2 shedding triggered by human adenoviruses Ad3, Ad14, and Ad14P1","volume":"89","author":"Wang","year":"2015","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0230","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.006_bib0231","doi-asserted-by":"crossref","first-page":"150","DOI":"10.18632\/oncotarget.1430","article-title":"Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0232","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/nbt887","article-title":"E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models","volume":"21","author":"Wang","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/bs.acr.2026.02.006_bib0233","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/5584_2016_135","article-title":"Syrian hamsters as a small animal model for emerging infectious diseases: Advances in immunologic methods","volume":"972","author":"Warner","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/bs.acr.2026.02.006_bib0234","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fgene.2016.00078","article-title":"Engineered swine models of cancer","volume":"7","author":"Watson","year":"2016","journal-title":"Front Genet"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0235","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/hum.2011.071","article-title":"Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model","volume":"22","author":"Weaver","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/bs.acr.2026.02.006_bib0236","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2741\/1604","article-title":"Functions of the adenovirus E4 proteins and their impact on viral vectors","volume":"10","author":"Weitzman","year":"2005","journal-title":"Front Biosci"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.006_bib0237","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/v13071300","article-title":"Genetic and chemical capsid modifications of adenovirus vectors to modulate vector-host interactions","volume":"13","author":"Weklak","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0238","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0239","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/JVI.79.4.1992-2000.2005","article-title":"Adenovirus protein VI mediates membrane disruption following capsid disassembly","volume":"79","author":"Wiethoff","year":"2005","journal-title":"J Virol"},{"issue":"20","key":"10.1016\/bs.acr.2026.02.006_bib0240","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.18632\/oncotarget.26754","article-title":"An oncolytic adenovirus 11p vector expressing adenovirus death protein in the E1 region showed significant apoptosis and tumour-killing ability in metastatic prostate cells","volume":"10","author":"Wu","year":"2019","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/bs.acr.2026.02.006_bib0241","doi-asserted-by":"crossref","first-page":"12775","DOI":"10.1128\/JVI.76.24.12775-12782.2002","article-title":"Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon","volume":"76","author":"Wu","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/bs.acr.2026.02.006_bib0242","article-title":"Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors","volume":"6","author":"Yan","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.006_bib0243","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/cgt.2009.6","article-title":"INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: Comparison of biodistribution studies","volume":"16","author":"Ying","year":"2009","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.006_bib0244","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/mt.2012.116","article-title":"Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo","volume":"20","author":"Young","year":"2012","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0245","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.virol.2012.12.014","article-title":"Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera","volume":"437","author":"Yu","year":"2013","journal-title":"Virology"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.006_bib0246","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1602670","article-title":"Cryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses","volume":"3","author":"Yu","year":"2017","journal-title":"Sci Adv"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.006_bib0247","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1101\/gad.10.12.1557","article-title":"Selective translation initiation by ribosome jumping in adenovirus-infected and heat-shocked cells","volume":"10","author":"Yueh","year":"1996","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.006_bib0248","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/hum.2016.022","article-title":"Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models","volume":"27","author":"Yumul","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0249","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/v17020162","article-title":"Ad6-based GM-CSF expressing vector displays oncolytic and immunostimulatory effects in an immunocompetent syrian hamster model of cholangiocarcinoma","volume":"17","author":"Zabelina","year":"2025","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.006_bib0250","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1265717","article-title":"Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy","volume":"6","author":"Zafar","year":"2017","journal-title":"OncoImmunology"},{"issue":"Pt 3","key":"10.1016\/bs.acr.2026.02.006_bib0251","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1099\/vir.0.18666-0","article-title":"Human adenovirus serotypes 4 and 11 show higher binding affinity and infectivity for endothelial and carcinoma cell lines than serotype 5","volume":"84","author":"Zhang","year":"2003","journal-title":"J Gen Virol"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.006_bib0252","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1158\/1535-7163.MCT-12-0157","article-title":"MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer","volume":"11","author":"Zhang","year":"2012","journal-title":"Mol Cancer Ther"}],"container-title":["Advances in Cancer Research","Viruses as Therapeutic Agents for Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:57:56Z","timestamp":1780592276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X26000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443432361"],"references-count":255,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2026.02.006","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}